CHMP recommends Fetcroja, intended for the treatment of infections due to aerobic Gram-negative organisms .- Shionogi
Related news and insights
Roche has announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) granted conditional marketing authorisation of Carvykti ( ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.
Axsome Therapeutics, Inc. announced the publication of the results from the pivotal ASCEND Phase II clinical trial of AXS 05 (dextromethorphan-bupropion) in major depressive disorder (MDD).